HERZLIA, Israel–(BUSINESS WIRE)–Endospan, a pioneer in off-the-shelf endovascular repair of Aortic Arch Disease including aneurysms and dissections, today announced that it has appointed Kevin J. Mayberry as Chief Executive Officer (CEO), effective immediately. He replaces Alon Shalev, who will continue as a director of Endospan. Previously, Mayberry served in various R&D and […]
Peripheral/Endo
Reflow Medical announces enrollment of its first patients in the Wing-IT IDE clinical trial
San Clemente, Calif., March 12, 2018 /PRNewswire/ — Reflow Medical Inc., a developer of innovative medical devices to combat cardiovascular disease, announced that the first patients have been enrolled in a prospective, multi-center, non-randomized study intended to evaluate the ability of the Reflow Wingman Catheters to cross chronic total occlusions […]
XableCath Granted United States Patent for its Peripheral Arterial Catheters
SALT LAKE CITY–(BUSINESS WIRE)– XableCath, Inc., innovators of products designed to aid in the treatment of peripheral artery disease (PAD), announced that it has been granted a second U.S. Patent, No. 9,826,995, covering its XableCath™ catheter. The patent specifically describes a catheter that controls tissue contact and has a rigid […]
Cardiovascular Systems Presents LIBERTY 360° 18-Month Outcomes at CRT18 Interventional Cardiology Conference
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, presented 18-month outcomes from its LIBERTY 360° study at the Cardiovascular Research Technologies (CRT) 2018 interventional cardiology conference in Washington, D.C. The […]
Endologix, Inc. Announces Enrollment of the First Patient in EVAS2 IDE Clinical Study of the Nellix® EndoVascular Aneurysm Sealing System
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the first patient was treated in the EVAS2 IDE Confirmatory Clinical Study of the investigational Nellix® EndoVascular Aneurysm Sealing (EVAS) System by Sajjad M. Hussain, M.D., Chief of the Department of Vascular Surgery […]
Symic Bio Announces Results of Locally-Administered Therapeutic SB-030 in Preclinical Model of Vascular Intervention
SAN FRANCISCO, March 5, 2018 /PRNewswire/ — Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced results from a preclinical study of locally-applied therapeutic SB-030 in the reduction of inflammatory response and clot formation. In a porcine arteriovenous shunt model for vascular procedures such as bypass grafts and angioplasty, […]
Corindus Receives FDA Clearance for First Automated Robotic Movement in technIQ™ Series for CorPath GRX Platform
WALTHAM, Mass.–(BUSINESS WIRE)– Corindus Vascular Robotics Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first automated robotic movement designed for the CorPath GRX platform. The proprietary software feature, named “Rotate on Retract” […]
New Biocompatible Embolic Device to Control Blood Flow & Treat Tumors Presented at the Leipzig Interventional Congress (LINC)
GPX is a biocompatible gel-particle embolic device that transforms from low-viscosity particles in a syringe to a solid particle after injection into a vessel LEIPZIG, GERMANY, February 01, 2018 /24-7PressRelease/ — Two scientific abstracts of a new vascular embolic device were presented this week at the 2018 Leipzig Interventional Congress […]
Abbott and Surmodics Announce Agreement for Next-Generation Drug-Coated Balloon
ABBOTT PARK, Ill. and EDEN PRAIRIE, Minn., Feb. 27, 2018 /PRNewswire/ — Abbott (NYSE: ABT) and Surmodics (NASDAQ: SRDX) today announced that the companies have entered into an agreement whereby Abbott will have exclusive worldwide commercialization rights for Surmodics’ SurVeil® drug-coated balloon to treat the superficial femoral artery, which is currently being evaluated in a U.S. pivotal […]
John McDermott Steps Down as Chief Executive Officer of Endologix, Inc.
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott is stepping down as the Company’s Chief Executive Officer. To facilitate a smooth transition, Mr. McDermott has committed to remaining in his current role until a successor is found. Daniel T. […]



